PharmaResearch Croissance future

Future contrôle des critères 5/6

PharmaResearch devrait augmenter ses bénéfices et son chiffre d'affaires de 25.3% et de 24.1% par an respectivement. Le BPA devrait croître de de 23% par an. Le rendement des capitaux propres devrait être 22.7% dans 3 ans.

Informations clés

25.3%

Taux de croissance des bénéfices

23.0%

Taux de croissance du BPA

Biotechs croissance des bénéfices	81.6%
Taux de croissance des recettes	24.1%
Rendement futur des capitaux propres	22.7%
Couverture par les analystes	Good
Dernière mise à jour	20 Nov 2024

Mises à jour récentes de la croissance future

Recent updates

PharmaResearch Co., Ltd. (KOSDAQ:214450) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Aug 15

Here's Why We Think PharmaResearch (KOSDAQ:214450) Might Deserve Your Attention Today

May 21

PharmaResearch Co., Ltd.'s (KOSDAQ:214450) 33% Share Price Surge Not Quite Adding Up

Apr 09

Is Pharma Research Products (KOSDAQ:214450) A Risky Investment?

Mar 23

Are Investors Undervaluing Pharma Research Products Co., Ltd (KOSDAQ:214450) By 50%?

Mar 05

Should You Be Adding Pharma Research Products (KOSDAQ:214450) To Your Watchlist Today?

Feb 17

Introducing Pharma Research Products (KOSDAQ:214450), A Stock That Climbed 65% In The Last Year

Feb 02

Pharma Research Products Co., Ltd (KOSDAQ:214450) Is Yielding 0.5% - But Is It A Buy?

Jan 20

Here's What Pharma Research Products Co., Ltd's (KOSDAQ:214450) Shareholder Ownership Structure Looks Like

Jan 07

Declining Stock and Solid Fundamentals: Is The Market Wrong About Pharma Research Products Co., Ltd (KOSDAQ:214450)?

Dec 23

Is Pharma Research Products (KOSDAQ:214450) Using Too Much Debt?

Dec 08

Is Pharma Research Products Co., Ltd (KOSDAQ:214450) Trading At A 43% Discount?

Nov 25

Prévisions de croissance des bénéfices et des revenus

KOSDAQ:A214450 - Estimations futures des analystes et données financières antérieures (KRW Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	541,085	168,240	141,640	159,067	7
12/31/2025	428,888	137,717	114,250	127,986	8
12/31/2024	340,754	102,983	89,683	107,757	7
6/30/2024	296,594	90,744	76,811	104,279	N/A
3/31/2024	280,285	76,092	70,589	85,849	N/A
12/31/2023	261,011	76,551	52,260	64,945	N/A
9/30/2023	244,661	64,902	41,817	53,239	N/A
6/30/2023	222,030	55,615	43,861	57,280	N/A
3/31/2023	204,932	48,964	46,461	61,734	N/A
12/31/2022	194,759	40,577	41,686	59,404	N/A
9/30/2022	183,191	46,501	43,484	65,744	N/A
6/30/2022	175,719	42,366	42,071	65,573	N/A
3/31/2022	164,813	43,752	38,455	62,868	N/A
12/31/2021	154,083	46,689	41,866	65,297	N/A
9/30/2021	143,282	47,110	36,738	58,386	N/A
6/30/2021	133,706	41,534	7,076	45,944	N/A
3/31/2021	122,609	40,153	6,042	43,936	N/A
12/31/2020	108,746	32,774	-2,991	32,392	N/A
9/30/2020	101,282	27,003	-4,928	27,003	N/A
6/30/2020	91,747	23,109	13,967	23,521	N/A
3/31/2020	84,091	16,407	11,603	18,946	N/A
12/31/2019	83,872	16,667	9,489	19,272	N/A
9/30/2019	77,416	19,060	250	12,948	N/A
6/30/2019	73,324	16,384	-7,794	13,176	N/A
3/31/2019	70,242	15,310	-12,069	8,818	N/A
12/31/2018	64,281	14,408	-19,414	5,203	N/A
9/30/2018	61,865	6,913	-13,353	6,975	N/A
6/30/2018	60,777	11,134	-9,967	7,070	N/A
3/31/2018	56,519	12,579	N/A	5,562	N/A
12/31/2017	54,470	12,956	N/A	8,555	N/A
9/30/2017	50,615	14,522	N/A	8,312	N/A
6/30/2017	47,241	13,472	N/A	6,052	N/A
3/31/2017	46,580	14,378	N/A	7,680	N/A
12/31/2016	45,953	13,909	N/A	8,161	N/A
9/30/2016	45,092	16,725	N/A	10,507	N/A
12/31/2015	37,455	12,878	N/A	16,023	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de A214450 ( 25.3% par an) est supérieure au taux d'épargne ( 2.7% ).

Bénéfices vs marché: Les bénéfices de A214450 ( 25.3% par an) devraient croître plus lentement que le marché KR ( 29.5% par an).

Croissance élevée des bénéfices: Les bénéfices de A214450 devraient augmenter de manière significative au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de A214450 ( 24.1% par an) devrait croître plus rapidement que le marché KR ( 9.3% par an).

Croissance élevée des revenus: Le chiffre d'affaires de A214450 ( 24.1% par an) devrait croître plus rapidement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de A214450 devrait être élevé dans 3 ans ( 22.7 %)

PharmaResearch Croissance future

Future contrôle des critères 5/6

Informations clés

Mises à jour récentes de la croissance future

Price target increased by 8.7% to ₩276,000

Price target increased by 7.1% to ₩187,500

Price target increased by 19% to ₩158,750

Price target increased by 11% to ₩107,500

Price target decreased to ₩88,300

Consensus forecasts updated

Recent updates

Price target increased by 8.7% to ₩276,000

PharmaResearch Co., Ltd. (KOSDAQ:214450) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

New minor risk - Share price stability

New minor risk - Shareholder dilution

Price target increased by 7.1% to ₩187,500

Here's Why We Think PharmaResearch (KOSDAQ:214450) Might Deserve Your Attention Today

Investor sentiment improves as stock rises 18%

PharmaResearch Co., Ltd.'s (KOSDAQ:214450) 33% Share Price Surge Not Quite Adding Up

Full year 2023 earnings released: EPS: ₩7,571 (vs ₩4,067 in FY 2022)

Upcoming dividend of ₩660 per share at 0.6% yield

Price target increased by 19% to ₩158,750

Investor sentiment improves as stock rises 15%

Now 20% undervalued

New minor risk - Shareholder dilution

Now 20% undervalued

Price target increased by 11% to ₩107,500

Investor sentiment improves as stock rises 18%

Investor sentiment improves as stock rises 16%

Investor sentiment improves as stock rises 20%

Now 21% undervalued

Price target decreased to ₩88,300

Upcoming dividend of ₩600 per share

Consensus forecasts updated

Price target decreased to ₩96,500

Price target decreased to ₩100,000

Consensus forecasts updated

Price target increased to ₩112,500

Upcoming dividend of ₩500 per share

PharmaResearch Co., Ltd. (KOSDAQ:A214450) acquired Medicoson Co., Ltd.

Price target increased to ₩120,000

Consensus revenue estimates increase to ₩152.8m

Price target increased to ₩88,100

Is Pharma Research Products (KOSDAQ:214450) A Risky Investment?

Are Investors Undervaluing Pharma Research Products Co., Ltd (KOSDAQ:214450) By 50%?

Should You Be Adding Pharma Research Products (KOSDAQ:214450) To Your Watchlist Today?

Introducing Pharma Research Products (KOSDAQ:214450), A Stock That Climbed 65% In The Last Year

New 90-day high: ₩64,900

Pharma Research Products Co., Ltd (KOSDAQ:214450) Is Yielding 0.5% - But Is It A Buy?

New 90-day low: ₩53,900

Here's What Pharma Research Products Co., Ltd's (KOSDAQ:214450) Shareholder Ownership Structure Looks Like

Declining Stock and Solid Fundamentals: Is The Market Wrong About Pharma Research Products Co., Ltd (KOSDAQ:214450)?

New 90-day low: ₩56,100

Is Pharma Research Products (KOSDAQ:214450) Using Too Much Debt?

New 90-day low: ₩57,600

Is Pharma Research Products Co., Ltd (KOSDAQ:214450) Trading At A 43% Discount?

Third quarter 2020 earnings released: EPS ₩812

Price target raised to ₩78,433

New 90-day high - ₩63,300

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance